Oppenheimer Reiterates Perform on ACADIA Pharmaceuticals, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jay Olson has reiterated a 'Perform' rating on ACADIA Pharmaceuticals (ACAD) and maintained a $25 price target.

February 05, 2024 | 1:53 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Oppenheimer analyst Jay Olson reiterates a 'Perform' rating on ACADIA Pharmaceuticals and maintains a $25 price target.
The reiteration of the 'Perform' rating and maintenance of the $25 price target by Oppenheimer suggests a neutral outlook on ACADIA Pharmaceuticals' stock in the short term. This analysis is based on the current market performance and the analyst's expectations, indicating no significant changes or updates that could drastically affect the stock's performance. Therefore, the impact on the stock price is likely to be neutral.
CONFIDENCE 95
IMPORTANCE 70
RELEVANCE 90